Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 2289-2290, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soma, L.
Right arrow Articles by Kao, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soma, L.
Right arrow Articles by Kao, A.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:2289-2290.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

CA-125 Concentrations in Patients Awaiting Cardiac Transplantation

Lorinda Soma1, Michael Allen2, Lynda Tobin2, Colleen Ganster2, Margaret Bulley1, Jennifer Hunt3, Larry J. Kricka1, Marilyn Senior1 and Andrew Kao2a

1 University of Pennsylvania, Medical Center, Department of Pathology, and Laboratory Medicine, 7th Floor, Founders Bldg., 3400 Spruce St., Philadelphia, PA 19104

2 University of Pennsylvania Medical Center, Department of Medicine, Cardiology Division, 6 Penn Tower, 3400 Spruce St., Philadelphia, PA 19104

3 University of Pittsburgh, Department of Pathology, and Laboratory Medicine, 200 Lothrop St., Pittsburgh, PA 15213

aAuthor for correspondence. Fax 215-615-0828; e-mail andrew.kao@uphs.upenn.edu.

The first 20% of the full text of this article appears below.


To the Editor:

CA-125 (cancer antigen or carbohydrate antigen) is a high-molecular weight glycoprotein most appropriately used for monitoring treatment response and recurrence of ovarian carcinoma, with concentrations >35 units/mL indicating residual tumor. Serum concentrations have also been shown to correlate with ovarian tumor mass. Increases, although usually not as marked, have been seen in other conditions such as lung cancer, gastrointestinal cancer, abdominal miliary tuberculosis, endometriosis, pelvic inflammatory disease, and during ovulation in 1–2% of healthy women. Therefore, this serum marker is not recommended as a screening test for ovarian carcinoma (1)(2)(3).

Recently, at the University of Pennsylvania Medical Center, CA-125 was inadvertently ordered on a male heart . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.